A new colorectal cancer drug has shocked researchers with how effective it is against the highly dangerous disease, as it virtually cured it in every member of a clinical trial. Dostarlimab, a monoclonal antibody drug, smashed expectations in a recent trial sponsored by pharma giant GlaxoSmithKline (GSK). A year after the trial’s completion, each of the 18 participants had their disease go into complete remission, with doctors unable to find signs of the cancer in their body. While the trial was small, it is game-changing, and sets up the drug as a potential cure for one of the most dangerous …read more
Source: Sott health news feed
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr